跳到正文
原文
STAT 主站· Jason Mast·· 3 天前AI 评分45

Capsida 基因治疗临床试验致死后,研究者公布改善猴子风险检测的方法

STAT+: After death in gene therapy trial for a brain disease, progress is reported

AI 导读

Capsida Biotherapeutics 研究人员公布了一项针对基因治疗临床试验中患者死亡的调查结果,提出用改进方法检测猴子中的新型风险。研究未确认导致该患者死亡的确切原因。首席研究与创新官 Nicholas Flytzanis 称正着手建立一套可测试和预测风险的框架,用于筛查未来疗法。

正文

Capsida scientists suggest they have found better way to test risk in monkeys

Adobe

By Jason Mast

Nov. 17, 2026

General Assignment Reporter

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

Researchers on Friday presented detailed investigations into a gene therapy death that sparked fear and uncertainty last year among scientists who felt they had been approaching powerful treatments for a long list of brain diseases.

The researchers did not conclude precisely what led to the patient’s death but proposed experiments to screen future therapies.

“What I want everyone to take home is: I think we’re starting to build a framework for testing this,” said Nicholas Flytzanis, chief research and innovation officer at Capsida Biotherapeutics. “I think it can be tested, and I think this specific novel risk is one that we can try to mitigate and predict in the future.”

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. General Assignment Reporter

    Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

来源:STAT 主站 · statnews.com